Ph.D., CEO, Medcurio, Inc.
Biography
Buzz Stewart has a long-standing interest in eliminating barriers to using data in real time to transform healthcare. During his more than 20 years of experience in healthcare delivery R&D, he has leveraged electronic health records and other sources of data to optimize healthcare delivery and scale precision medicine and clinal trails research. Buzz has designed and evaluated new models of care, developed streamlined process for biobanking, and used machine learning to develop predictive and phenotyping models. He is the co-founder and CEO of Medcurio, Inc, a start-up offering a seamless healthcare data access solution that eliminates the friction to getting and using data. He was previously Sutter Health’s Chief Research Officer (2012-2018), the founder of Geisinger’s Center for Health Research (2003-2012), VP of R&D, AdvancePCS (1998-2002), and faculty at the Johns Hopkins Bloomberg School of Public Health (1983-1995). Buzz received his Ph.D. from Johns Hopkins and MPH from UCLA.
Clinical & Research Tools Showcase:
Medcurio, Inc.
Medcurio, Inc. is a start-up that makes it easy to access, use, and learn from data in real time. Their platform enables non-technical users to develop and maintain APIs for real-time access to all healthcare data without writing any code.
Precision Medicine In Real Time, For Real!
Medcurio enables the delivery of precise data and guidance at the right time and place, for the right person, eliminating the headaches to getting and maintaining real-time data access. Real-word applications will be described.
Session Abstract – PMWC 2020 Silicon Valley
Track 6 - January 23 4.30 P.M.-4.45 P.M.,Track 7 - January 24 9.00 A.M.-10.45 A.M.
The PMWC 2020 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.
